New convertible debt financing with existing long-term equity shareholders yields ~$18M in net cash proceeds after paying off existing convertible debtNEW YORK, Dec. 3, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the successful completion of a convertible debt refinancing transaction that strengthens its balance sheet and extends its cash ...

The share price of luxury electric vehicle manufacturer Lucid (NASDAQ: LCID) is aiming to build on recent gains and solidify its price above the $2 support, as the technical setup suggests what to expect.At the close of the last trading session, LCID was valued at $2.17, ending the day up 1.64%. This builds on the bullish momentum witnessed on the weekly chart, where the EV’s stock has gained 4.3%. Overall, this short-term momentum has done little to change Lucid’s fortunes in 2024, where the equity is down ...

Over the past five days, Lucid Group (NASDAQ: LCID) stock has gained 4.89% but remains down 13.89% over the past month. Lucid briefly fell below the psychological $2 level, sparking concerns among investors, but it has since clawed its way back into safer territory. Lucid 5-day stock chart. Source: FinboldDespite this modest recovery, Lucid continues to trade near the lower end of its 52-week range, signaling broader challenges for the electric vehicle (EV) manufacturer. Analysts set Lucid Motors price targ ...

Lucid may drive a different path with EVs than its rivals -- can it work?Sometimes, when you zig and everyone else zags, you come out ahead in a big way. That's similar to what Lucid Group (LCID 3.33%) seems to be doing with its product pipeline strategy. At a time when most automakers are engaged in a race to the bottom -- offering affordable electric vehicle (EV) around $20,000 to $25,000 -- Lucid doesn't want much to do with that market.In fact, two historically important types of vehicles won't be found ...

Just like that, with the 2024 Presidential election in the books, electric vehicle (EV) investors are left to wonder if the U.S. is about to hit a major industry speed bump. President-elect Donald Trump has occasionally spoken out against EVs, and the transition team is rumored to be heavily considering ending the $7,500 federal tax credit, which could soften EV demand.But if Lucid Group (LCID 1.94%) CEO Peter Rawlinson is to be believed, Lucid's investors might not have much to worry about. Here's why.Tran ...

Lucid's deliveries are accelerating, but its stock price is stalling. Is this the opportunity for investors to jump in?If you've been following the electric vehicle (EV) industry, it's been an interesting ride so far. Some global markets are exploding much faster than North America, especially when you look at China, where recent monthly EV sales accounted for more than 50% of new vehicle sales. Lucid (LCID 1.94%) in particular has captured momentum, seemingly at the expense of rival Rivian, but is it a buy ...

Core Viewpoint - The electric vehicle (EV) market is expected to grow, but not all EV companies, including Lucid, are viable investments due to challenges in profitability and increasing competition [1] Group 1: Competitive Landscape - Tesla serves as a benchmark for Lucid, showcasing positive margins and free cash flow, but has faced margin compression due to price cuts in 2023 [2] - The automotive industry is characterized by high marginal and inventory costs, with increasing EV supply not matching demand, leading to lower prices and margins [2] Group 2: Lucid's Financial Challenges - Lucid's gross margins are negative at -106%, indicating significant difficulties in achieving profitability [3] - The starting price of Lucid vehicles at $69,900 limits their market reach, making it challenging to scale production beyond the anticipated 9,000 vehicles for the year [4] - High operational costs in the luxury market hinder Lucid's ability to generate profits at low volumes [5] Group 3: Debt and Cash Flow Situation - Lucid is facing mounting losses and has $2 billion in debt, with dwindling cash reserves of $1.894 billion, raising concerns about its financial sustainability [6][8] - The Saudi Arabia Public Investment Fund (PIF) has committed $750 million in preferred shares and a similar amount in a loan facility, but these funds are prioritized over common shareholders, leaving Lucid's future uncertain [7] - Without additional capital, Lucid has only about a year of cash left, complicating future fundraising efforts due to a declining stock price [9] Group 4: Overall Outlook - The combination of losses, a challenging balance sheet, and a competitive environment presents a daunting situation for Lucid, making it difficult to envision a path to sustainability [10] - Current assessments suggest that Lucid's stock is not a viable buy, with a downward spiral expected to continue [10]

A financial researcher and avid investor with a keen eye for innovation and disruption, as well as growth buy-outs and value stocks. Keeping an eye on the pace of high tech and early growth companies, I write about current events and the biggest news surrounding the industry, and strive to provide readers with ample research and investment opportunities.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positio ...

NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Lucid Group (NASDAQ: LCID) on behalf of long-term stockholders following a class action complaint that was filed against Lucid on April 1, 2022 with a Class Period from November 15, 2021 to August 3, 2022. Our investigation concerns whether the board of directors of Lucid have breached their fiduciary duties to the company. The Lucid class-ac ...

NEW YORK, Nov. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has submitted its complete clinical evidence package for its EsoGuard® Esophageal DNA Test in support of a Request for Reconsideration of Local Coverage Determination (LCD) L39256 "MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, an ...